Trelegy Ellipta pack shot
A simple choice. One inhaler, easy to use and quick to teach1

With >99% of patients able to generate the inspiratory flow required, Ellipta ensures even your severe COPD patients get the dose they need2,3

Dosing | The recommended and maximum dose is one inhalation of Trelegy Ellipta 92/55/22 micrograms once daily, at the same time each day. If a dose is missed the next dose should be inhaled at the usual time the next day.4

The Ellipta device - patient preferred and easy-to-use1

See below to compare critical errors of commonly used devices

Critical errors graph

Adapted from Van der Palen J et al. 2016

Open label, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)

Ellipta patients made fewer critical errors after reading the PIL compared with other common COPD inhalersg
*Critical error defined as errors that are likely to result in no, or minimal medication being delivered to the lungs.
In the INTREPID trial, the % of patients with ≥1 critical error in inhalation technique at week 24 was: 6% in the FF/UMEC/VI treatment group, 3% in the non-Ellipta multiple inhaler triple therapy group. OR: 1.99; p=0.103 (NS)

81% of COPD patients on triple therapy in multiple inhalers are dealing with both once and twice daily dosing6

Where patients are using several classes of inhalers and poor inhaler technique is identified with once device, the DPI class should be prioritised if the patient is able to use these safely.7

Different triple therapy combinations

This figure does not represent all inhalers of all possible combinations. Trademarks are the property of their perspective owners.


Trelegy Ellipta pack shot

A single inhaler triple therapy

How to Use the Trelegy Ellipta Inhaler

See how easy it is for patients to use the Ellipta inhaler device as part of daily life.

Support your patients starting on Trelegy Ellipta

Prescribing Information Links

Trelegy Ellipta Prescribing Information (pdf)

Seretide Accuhaler Prescribing Information (pdf)

Incruse Ellipta Prescribing information (pdf)

Relvar Ellipta Prescribing Information (pdf)

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.4

Seretide accuhaler is indicated for symptomatic treatment of patients with COPD with a FEV1 <60% predicted normal (prebronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy5

Relvar Ellipta OD is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy.8

Incruse Ellipta OD is indicated for maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)9


ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; DPI, dry powder inhaler; MDI, metered-dose inhaler; pMDI, pressurised metered-dose inhaler, OD, once daily.


  1. van der Palen J et al. NPJ Prim Care Med 2016; 26:16079
  2. Anderson M, et al. Int J Chron Obstruct Pulmon Dis. 2021 Apr12;16:933-943
  3. Prime D, et al. CHEST. 2019;156:A1786
  4. Trelegy SmPC
  5. Seretide SmPC
  6. IQVIA DRx Patients on Treatment Sept 2021 - August 2022
  7. BTS Position Statement - The environment and lung health 2020
  8. Relvar Ellipta SmPC
  9. Incruse Ellipta SmPC
  10. Halpin, D et al 2021. INTREPID: single- versus multiple inhaler triple therapy for COPD in usual clinical practice. ERJ Open Research, pp00950-2020. No 824


Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

February 2023 | PM-GB-FVU-WCNT-200008 (V5.0)